1. Home
  2. REGN vs PSX Comparison

REGN vs PSX Comparison

Compare REGN & PSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REGN
  • PSX
  • Stock Information
  • Founded
  • REGN 1988
  • PSX 1875
  • Country
  • REGN United States
  • PSX United States
  • Employees
  • REGN N/A
  • PSX N/A
  • Industry
  • REGN Biotechnology: Pharmaceutical Preparations
  • PSX Integrated oil Companies
  • Sector
  • REGN Health Care
  • PSX Energy
  • Exchange
  • REGN Nasdaq
  • PSX Nasdaq
  • Market Cap
  • REGN 59.9B
  • PSX 50.5B
  • IPO Year
  • REGN 1991
  • PSX 2012
  • Fundamental
  • Price
  • REGN $558.87
  • PSX $119.59
  • Analyst Decision
  • REGN Buy
  • PSX Buy
  • Analyst Count
  • REGN 21
  • PSX 16
  • Target Price
  • REGN $823.86
  • PSX $136.87
  • AVG Volume (30 Days)
  • REGN 940.4K
  • PSX 2.8M
  • Earning Date
  • REGN 08-01-2025
  • PSX 07-25-2025
  • Dividend Yield
  • REGN 0.63%
  • PSX 4.01%
  • EPS Growth
  • REGN 5.03
  • PSX N/A
  • EPS
  • REGN 39.67
  • PSX 4.14
  • Revenue
  • REGN $14,214,200,000.00
  • PSX $132,966,000,000.00
  • Revenue This Year
  • REGN N/A
  • PSX N/A
  • Revenue Next Year
  • REGN $6.65
  • PSX $0.49
  • P/E Ratio
  • REGN $14.09
  • PSX $28.90
  • Revenue Growth
  • REGN 5.38
  • PSX N/A
  • 52 Week Low
  • REGN $476.49
  • PSX $91.01
  • 52 Week High
  • REGN $1,211.20
  • PSX $147.14
  • Technical
  • Relative Strength Index (RSI)
  • REGN 54.16
  • PSX 40.07
  • Support Level
  • REGN $541.61
  • PSX $122.56
  • Resistance Level
  • REGN $563.59
  • PSX $128.52
  • Average True Range (ATR)
  • REGN 15.37
  • PSX 2.83
  • MACD
  • REGN -0.75
  • PSX -0.99
  • Stochastic Oscillator
  • REGN 41.57
  • PSX 3.68

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

About PSX Phillips 66

Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 1.8 million barrels per day, or mmb/d. In 2023, the Rodeo, California, facility ceased operations and be converted to produce renewable diesel. The midstream segment comprises extensive transportation and NGL processing assets and includes DCP Midstream, which holds 600 mbd of NGL fractionation and 22,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.

Share on Social Networks: